To further analyse the mutation frequency of ROBO1 and ROBO2, we performed targeted deep sequencing in a cohort of 193 patients with primary MDS who received no treatment (Supplementary Table 7). This evidence concerns the gene ROBO2 and myelodysplastic syndrome.